200 related articles for article (PubMed ID: 26713839)
21. Pegylated long-acting human growth hormone is well-tolerated in healthy subjects and possesses a potential once-weekly pharmacokinetic and pharmacodynamic treatment profile.
Rasmussen MH; Bysted BV; Anderson TW; Klitgaard T; Madsen J
J Clin Endocrinol Metab; 2010 Jul; 95(7):3411-7. PubMed ID: 20427496
[TBL] [Abstract][Full Text] [Related]
22. Administration of growth hormone and nandrolone decanoate alters mRNA expression of the GABAB receptor subunits as well as of the GH receptor, IGF-1, and IGF-2 in rat brain.
Grönbladh A; Johansson J; Nyberg F; Hallberg M
Growth Horm IGF Res; 2014; 24(2-3):60-6. PubMed ID: 24480470
[TBL] [Abstract][Full Text] [Related]
23. Intranasal Human Growth Hormone (hGH) Induces IGF-1 Levels Comparable With Subcutaneous Injection With Lower Systemic Exposure to hGH in Healthy Volunteers.
Lewis AL; Jordan F; Patel T; Jeffery K; King G; Savage M; Shalet S; Illum L
J Clin Endocrinol Metab; 2015 Nov; 100(11):4364-71. PubMed ID: 26425883
[TBL] [Abstract][Full Text] [Related]
24. Sustained release hGH microsphere formulation produced by a novel supercritical fluid technology: in vivo studies.
Jordan F; Naylor A; Kelly CA; Howdle SM; Lewis A; Illum L
J Control Release; 2010 Jan; 141(2):153-60. PubMed ID: 19772878
[TBL] [Abstract][Full Text] [Related]
25. A Randomized Safety and Efficacy Study of Somavaratan (VRS-317), a Long-Acting rhGH, in Pediatric Growth Hormone Deficiency.
Moore WV; Nguyen HJ; Kletter GB; Miller BS; Rogers D; Ng D; Moore JA; Humphriss E; Cleland JL; Bright GM
J Clin Endocrinol Metab; 2016 Mar; 101(3):1091-7. PubMed ID: 26672637
[TBL] [Abstract][Full Text] [Related]
26. Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: comparison of two dosage levels and to GH-treated GH deficiency.
Guevara-Aguirre J; Rosenbloom AL; Vasconez O; Martinez V; Gargosky SE; Allen L; Rosenfeld RG
J Clin Endocrinol Metab; 1997 Feb; 82(2):629-33. PubMed ID: 9024266
[TBL] [Abstract][Full Text] [Related]
27. Equivalent potency and pharmacokinetics of recombinant human growth hormones with or without an N-terminal methionine.
Moore JA; Rudman CG; MacLachlan NJ; Fuller GB; Burnett B; Frane JW
Endocrinology; 1988 Jun; 122(6):2920-6. PubMed ID: 3371267
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics and pharmacodynamics of single-chain recombinant human follicle-stimulating hormone containing the human chorionic gonadotropin carboxyterminal peptide in the rhesus monkey.
Klein J; Lobel L; Pollak S; Ferin M; Xiao E; Sauer M; Lustbader JW
Fertil Steril; 2002 Jun; 77(6):1248-55. PubMed ID: 12057736
[TBL] [Abstract][Full Text] [Related]
29. Immunogenicity, toxicology, pharmacokinetics and pharmacodynamics of growth hormone ligand-receptor fusions.
Ferrandis E; Pradhananga SL; Touvay C; Kinoshita C; Wilkinson IR; Stafford K; Wu Z; Strasburger CJ; Sayers JR; Artymiuk PJ; Ross RJ
Clin Sci (Lond); 2010 Aug; 119(11):483-91. PubMed ID: 20597861
[TBL] [Abstract][Full Text] [Related]
30. A pharmacokinetic/pharmacodynamic model for recombinant human growth hormone effects on induction of insulin-like growth factor I in monkeys.
Sun YN; Lee HJ; Almon RR; Jusko WJ
J Pharmacol Exp Ther; 1999 Jun; 289(3):1523-32. PubMed ID: 10336548
[TBL] [Abstract][Full Text] [Related]
31. A long-acting human growth hormone with delayed clearance (VRS-317): results of a double-blind, placebo-controlled, single ascending dose study in growth hormone-deficient adults.
Yuen KC; Conway GS; Popovic V; Merriam GR; Bailey T; Hamrahian AH; Biller BM; Kipnes M; Moore JA; Humphriss E; Bright GM; Cleland JL
J Clin Endocrinol Metab; 2013 Jun; 98(6):2595-603. PubMed ID: 23585663
[TBL] [Abstract][Full Text] [Related]
32. Differential regulation by growth hormone (GH) of insulin-like growth factor I and GH receptor/binding protein gene expression in rat liver.
Maiter D; Walker JL; Adam E; Moatsstaats B; Mulumba N; Ketelslegers JM; Underwood LE
Endocrinology; 1992 Jun; 130(6):3257-64. PubMed ID: 1375898
[TBL] [Abstract][Full Text] [Related]
33. The effect of polyethylene glycol recombinant human growth hormone on growth and glucose metabolism in hypophysectomized rats.
Zhang ZX; Liu YK; Pan H; Pan L; Zhang Q; Su HM; Zhao QL; Li H; He C
Growth Horm IGF Res; 2012 Feb; 22(1):30-5. PubMed ID: 22257554
[TBL] [Abstract][Full Text] [Related]
34. Increased expression of insulin-like growth factor-I in serum and liver after recombinant human growth hormone administration in thermally injured rats.
Jeschke MG; Chrysopoulo MT; Herndon DN; Wolf SE
J Surg Res; 1999 Jul; 85(1):171-7. PubMed ID: 10383855
[TBL] [Abstract][Full Text] [Related]
35. Safety and PK/PD correlation of TV-1106, a recombinant fused human albumin-growth hormone, following repeat dose administration to monkeys.
Ashkenazi N; Rosenstock M; Hallak H; Bassan M; Rasamoelisolo M; Leuschner J; Shinar D
Growth Horm IGF Res; 2016; 30-31():16-21. PubMed ID: 27552669
[TBL] [Abstract][Full Text] [Related]
36. Human growth hormone fragments 1-43 and 44-191: in vitro somatogenic activity and receptor binding characteristics in human and nonprimate systems.
Rowlinson SW; Waters MJ; Lewis UJ; Barnard R
Endocrinology; 1996 Jan; 137(1):90-5. PubMed ID: 8536647
[TBL] [Abstract][Full Text] [Related]
37. N-Terminal Modification with Pseudo-Bifunctional PEG-Hexadecane Markedly Improves the Pharmacological Profile of Human Growth Hormone.
Wu L; Ji S; Hu T
Mol Pharm; 2015 May; 12(5):1402-11. PubMed ID: 25849255
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetic/pharmacodynamic (PK/PD) differentiation of native and PEGylated recombinant human growth hormone (rhGH and PEG-rhGH) in the rat model of osteoarthritis.
Nemirovskiy O; Zheng YJ; Tung D; Korniski B; Settle S; Skepner A; Yates M; Aggarwal P; Sunyer T; Aguiar DJ
Xenobiotica; 2010 Aug; 40(8):586-92. PubMed ID: 20509748
[TBL] [Abstract][Full Text] [Related]
39. Long-acting FC-fusion rhGH (GX-H9) shows potential for up to twice-monthly administration in GH-deficient adults.
Ku CR; Brue T; Schilbach K; Ignatenko S; Magony S; Chung YS; Kim BJ; Hur KY; Kang HC; Kim JH; Kim MS; Kowalska A; Bolanowski M; Ruchala M; Damjanovic S; Payer J; Choi YJ; Heo SJ; Kim TK; Heo M; Lee J; Lee EJ
Eur J Endocrinol; 2018 Sep; 179(3):169-179. PubMed ID: 29973375
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of LB03002, a once-weekly sustained-release human GH for 12-month treatment in Korean children with GH deficiency.
Hwang JS; Lee HS; Chung WY; Han HS; Jin DK; Kim HS; Ko CW; Lee BC; Lee DY; Lee KH; Shin JH; Suh BK; Yoo HW; Ji HJ; Lee JH; Bae YJ; Kim DH; Yang SW
Eur J Endocrinol; 2013 Aug; 169(2):179-85. PubMed ID: 23682096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
